Cargando…

Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells

BACKGROUND: The aim of this in vitro study was to measure the enhanced anticancer effects of Res (resveratrol) on PA (paclitaxel) in HepG2 human liver cancer cells. METHODS: The MTT (thiazolyl blue tetrazolium bromide, 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide), flow cytometry, qP...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Qin, Yang, Manyi, Qu, Zhan, Zhou, Jixiang, Zhang, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628430/
https://www.ncbi.nlm.nih.gov/pubmed/28978315
http://dx.doi.org/10.1186/s12906-017-1956-0
_version_ 1783268881528258560
author Jiang, Qin
Yang, Manyi
Qu, Zhan
Zhou, Jixiang
Zhang, Qi
author_facet Jiang, Qin
Yang, Manyi
Qu, Zhan
Zhou, Jixiang
Zhang, Qi
author_sort Jiang, Qin
collection PubMed
description BACKGROUND: The aim of this in vitro study was to measure the enhanced anticancer effects of Res (resveratrol) on PA (paclitaxel) in HepG2 human liver cancer cells. METHODS: The MTT (thiazolyl blue tetrazolium bromide, 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide), flow cytometry, qPCR (real-time quantitative polymerase chain reaction) and western blot assay were used for cells growth inhibitory effects, cells apoptosis (DNA content of sub-G1), mRNA and protein expressions, respectively. RESULTS: The 10 μg/mL of Res had no growth inhibitory effect on Nthy-ori 3–1 normal cells or HepG2 cancer cells meanwhile the 5 or 10 μg/mL of PA also had no growth inhibitory effect on Nthy-ori 3–1 normal cells. Where as PA-L (5 μg/mL) and PA-H (10 μg/mL) had the growth inhibitory effects in HepG2 cancer cells, and Res increase these growth inhibitory effects. By flow cytometry experiment, after Res (5 μg/mL) + PA-H (10 μg/mL) treatment, the HepG2 cells showed the most apoptosis in cells as compared to other treatments groups, and after additionally treated with Res, both the apoptosis cells of two concentrations PA were raised. As PA raised it also raised the mRNA and protein expressions of caspase-3, caspase-8, caspase-9, Bax (Bcl-2 assaciated X protein), p53, p21, IκB-α (inhibitor of NF-κB alpha), Fas (factor associated suicide), FasL (factor associated suicide ligand), TIMP-1 (tissue inhibitor of metalloproteinases 1), TIMP-2 (tissue inhibitor of metalloproteinases 2) and decrease Bcl-2 (B cell leukemia 2), Bcl-xL (B cell leukemia extra large), HIAP-1 (cIAP-1, cellular inhibitor of apoptosis 1), HIAP-2 (cIAP-2, cellular inhibitor of apoptosis 2), NF-κB (nuclear factor kappa B), COX-2 (cyclooxygenase 2), iNOS (inducible nitric oxide synthase), MMP-2 (metalloproteinase 2), MMP-9 (metalloproteinase 9), EGF (epidermal growth factor), EGFR (epidermal growth factor receptor), VEGF (vascular endothelial growth factor), Fit-1 (VEGFR-1, vascular endothelial growth factor receptor 1). Meanwhile, the 5 μg/mL of Res could enhance these mRNA expressions changes as compared to the control cells. CONCLUSION: From these results, we can conclude that Res could raise the anticancer effects of PA in HepG2 cells, Res could be used as a good sensitizing agent for PA.
format Online
Article
Text
id pubmed-5628430
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56284302017-10-13 Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells Jiang, Qin Yang, Manyi Qu, Zhan Zhou, Jixiang Zhang, Qi BMC Complement Altern Med Research Article BACKGROUND: The aim of this in vitro study was to measure the enhanced anticancer effects of Res (resveratrol) on PA (paclitaxel) in HepG2 human liver cancer cells. METHODS: The MTT (thiazolyl blue tetrazolium bromide, 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide), flow cytometry, qPCR (real-time quantitative polymerase chain reaction) and western blot assay were used for cells growth inhibitory effects, cells apoptosis (DNA content of sub-G1), mRNA and protein expressions, respectively. RESULTS: The 10 μg/mL of Res had no growth inhibitory effect on Nthy-ori 3–1 normal cells or HepG2 cancer cells meanwhile the 5 or 10 μg/mL of PA also had no growth inhibitory effect on Nthy-ori 3–1 normal cells. Where as PA-L (5 μg/mL) and PA-H (10 μg/mL) had the growth inhibitory effects in HepG2 cancer cells, and Res increase these growth inhibitory effects. By flow cytometry experiment, after Res (5 μg/mL) + PA-H (10 μg/mL) treatment, the HepG2 cells showed the most apoptosis in cells as compared to other treatments groups, and after additionally treated with Res, both the apoptosis cells of two concentrations PA were raised. As PA raised it also raised the mRNA and protein expressions of caspase-3, caspase-8, caspase-9, Bax (Bcl-2 assaciated X protein), p53, p21, IκB-α (inhibitor of NF-κB alpha), Fas (factor associated suicide), FasL (factor associated suicide ligand), TIMP-1 (tissue inhibitor of metalloproteinases 1), TIMP-2 (tissue inhibitor of metalloproteinases 2) and decrease Bcl-2 (B cell leukemia 2), Bcl-xL (B cell leukemia extra large), HIAP-1 (cIAP-1, cellular inhibitor of apoptosis 1), HIAP-2 (cIAP-2, cellular inhibitor of apoptosis 2), NF-κB (nuclear factor kappa B), COX-2 (cyclooxygenase 2), iNOS (inducible nitric oxide synthase), MMP-2 (metalloproteinase 2), MMP-9 (metalloproteinase 9), EGF (epidermal growth factor), EGFR (epidermal growth factor receptor), VEGF (vascular endothelial growth factor), Fit-1 (VEGFR-1, vascular endothelial growth factor receptor 1). Meanwhile, the 5 μg/mL of Res could enhance these mRNA expressions changes as compared to the control cells. CONCLUSION: From these results, we can conclude that Res could raise the anticancer effects of PA in HepG2 cells, Res could be used as a good sensitizing agent for PA. BioMed Central 2017-10-04 /pmc/articles/PMC5628430/ /pubmed/28978315 http://dx.doi.org/10.1186/s12906-017-1956-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Jiang, Qin
Yang, Manyi
Qu, Zhan
Zhou, Jixiang
Zhang, Qi
Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells
title Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells
title_full Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells
title_fullStr Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells
title_full_unstemmed Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells
title_short Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells
title_sort resveratrol enhances anticancer effects of paclitaxel in hepg2 human liver cancer cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628430/
https://www.ncbi.nlm.nih.gov/pubmed/28978315
http://dx.doi.org/10.1186/s12906-017-1956-0
work_keys_str_mv AT jiangqin resveratrolenhancesanticancereffectsofpaclitaxelinhepg2humanlivercancercells
AT yangmanyi resveratrolenhancesanticancereffectsofpaclitaxelinhepg2humanlivercancercells
AT quzhan resveratrolenhancesanticancereffectsofpaclitaxelinhepg2humanlivercancercells
AT zhoujixiang resveratrolenhancesanticancereffectsofpaclitaxelinhepg2humanlivercancercells
AT zhangqi resveratrolenhancesanticancereffectsofpaclitaxelinhepg2humanlivercancercells